Publications by authors named "J Y Helou"
Background: Exposure to Ultraviolet radiation (UVR) is a major risk factor for skin cancer. Data about UVR risk knowledge and exposure behaviors in the Lebanese population are scarce.
Aim: To evaluate the association between UVR risks knowledge, attitudes, and behaviors among Lebanese university students in the aim of promoting primary prevention of skin cancer.
Introduction: Recent advances in image-guided brachytherapy have allowed for treatment volume reduction in the treatment of prostate cancer, with the aim to optimize disease control and reduce toxicities. This systematic review reports on the efficacy and safety of focal brachytherapy for treatment of patients with localized prostate cancer.
Methods: Medline, Embase, Web of Science and Cochrane were searched from inception to July 2023.
Purpose: In oligoprogressive (OP) cancer, there are a limited number of metastatic areas progressing on a background of stable or responding to widespread cancer. Although the standard of care for OP is changing systemic therapy (ST), stereotactic body radiation therapy (SBRT) is being explored as an alternative local therapy targeting the sites of progression.
Methods And Materials: RADIANT (NCT04122469) was a single-center phase 2 study of patients with metastatic genitourinary (GU), breast, and gastrointestinal (GI) cancers, receiving ST for ≥3 months, with radiographic OP disease in ≤5 sites.
Article Synopsis
- - The SABR-SYNC trial aims to evaluate the effectiveness of stereotactic ablative radiotherapy (SABR) in patients with oligometastatic cancers that have a synchronous primary tumor, addressing a gap in phase III data currently available.
- - One hundred and eighty patients will be randomly assigned to receive either standard care treatment or standard care plus SABR, with various dosing and treatment modalities used depending on the physician's clinical judgement.
- - The trial will focus on overall survival as the main goal, while also examining factors like progression-free survival, quality of life, and potential biomarkers from circulating tumor DNA to improve future treatment decisions.